{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:42:55Z","timestamp":1740148975185,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s12325-017-0634-4","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T06:25:02Z","timestamp":1508999102000},"page":"2466-2480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults"],"prefix":"10.1007","volume":"34","author":[{"given":"Tomohiro","family":"Kusawake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"den Adel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorien","family":"Groenendaal-van de Meent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Garcia-Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitsugu","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Katashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"issue":"3","key":"634_CR1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.9.3.361","volume":"9","author":"AM Arvin","year":"1996","unstructured":"Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9(3):361\u201381.","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"634_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1365-2990.2011.01167.x","volume":"37","author":"D Gilden","year":"2011","unstructured":"Gilden D, Mahalingam R, Nagel MA, Pugazhenthi S, Cohrs RJ. Review: the neurobiology of varicella zoster virus infection. Neuropathol Appl Neurobiol. 2011;37(5):441\u201363.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"6","key":"634_CR3","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833.","journal-title":"BMJ Open"},{"key":"634_CR4","unstructured":"GlaxoSmithKline. ZOVIRAX\u00ae (acyclovir) capsules, tablets, suspension: prescribing information. 2005. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/018828s030,020089s019,019909s020lbl.pdf\n                    \n                  . Accessed 21 Jul 2017."},{"key":"634_CR5","unstructured":"GlaxoSmithKline. VALTREX\u00ae (valacyclovir hydrochloride) caplets: prescribing information. 2008. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020487s014lbl.pdf\n                    \n                  . Accessed 21 Jul 2017."},{"key":"634_CR6","unstructured":"Novartis. Famvir\u00ae (famciclovir) tablets: prescribing information. 2006. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/020363s026lbl.pdf\n                    \n                  . Accessed 21 July 2017."},{"issue":"8","key":"634_CR7","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/jac\/dkq198","volume":"65","author":"K Chono","year":"2010","unstructured":"Chono K, Katsumata K, Kontani T, et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother. 2010;65(8):1733\u201341.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"634_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.antiviral.2011.11.015","volume":"93","author":"T Himaki","year":"2012","unstructured":"Himaki T, Masui Y, Chono K, et al. Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo. Antiviral Res. 2012;93(2):301\u20134.","journal-title":"Antiviral Res"},{"issue":"2","key":"634_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10337-016-3236-4","volume":"80","author":"Y Ohtsu","year":"2017","unstructured":"Ohtsu Y, van Trigt R, Takama K, et al. Quantification of ASP2151 in human plasma and urine: a pitfall associated with supersaturation of analyte in urine. Chromatographia. 2017;80(2):217\u201327.","journal-title":"Chromatographia"},{"issue":"3","key":"634_CR10","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1128\/AAC.01803-12","volume":"57","author":"K Katsumata","year":"2013","unstructured":"Katsumata K, Chono K, Kato K, et al. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection. Antimicrob Agents Chemother. 2013;57(3):1339\u201346.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"634_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2051013615599151","volume":"3","author":"RW Johnson","year":"2015","unstructured":"Johnson RW, Alvarez-Pasquin MJ, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3(4):109\u201320.","journal-title":"Ther Adv Vaccines."},{"key":"634_CR12","doi-asserted-by":"crossref","unstructured":"Kusawake T, Keirns J, Kowalski D, et al. Pharmacokinetics and safety of amenamevir in healthy subjects: analysis of four randomized phase 1 studies. Advances in Therapy (under review).","DOI":"10.1007\/s12325-017-0642-4"},{"issue":"7","key":"634_CR13","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/infdis\/jis019","volume":"205","author":"S Tyring","year":"2012","unstructured":"Tyring S, Wald A, Zadeikis N, Dhadda S, Takenouchi K, Rorig R. ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study. J Infect Dis. 2012;205(7):1100\u201310.","journal-title":"J Infect Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0634-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0634-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0634-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T14:25:21Z","timestamp":1548080721000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0634-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["634"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0634-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2017,10,26]]},"assertion":[{"value":"1 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}